Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1386 • ACR Convergence 2024
Olokizumab in Real Clinical Practice: Efficacy and Safety
Sofia Kuzkina¹, Alena Zagrebneva², Galym Togizbayev³, Elvira Aitova⁴, Nataliya Belozerova⁵, Irina Patrikeeva⁶, Ruzana Samigullina⁷, Mikhail Sostak⁷, Evgeniya Jakovleva⁸, Anton Chudinov⁹, Antonina Dolgorukova¹⁰, Evgeniy Alekseev¹¹ and EVGENY NASONOV¹², ¹R-Pharm, Moscow, Russia, ²Clinical hospital #52, Moscow, Russia, ³Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, ⁴Clinic of Bashkir State Medical University, Ufa, Russia, ⁵SBIHC «Region clinic hospital Nr 2»; SBEA HE «Kuban state medical university»,, Krasnodar, Russia, ⁶GBUZ Tyumen Regional Clinical Hospital N 1, Tyumen, Russia, ⁷North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia, ⁸Scientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1, Krasnodar, Russia, ⁹Clinical Rheumatology Hospital No.25; North-West State Medical University named after I.I.Mechnikov, Saint-Petersburg, Russia, ¹⁰R-Pharm, JSC, Moscow, Russia, ¹¹R-Pharm, JSC, Saint-Petersburg, Russia, ¹²V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University, Moscow, Russia
Background/Purpose: Olokizumab (OKZ) is a direct inhibitor of interleukin 6, which has shown significant symptom reduction in RA patients, however there is a lack of…
Abstract Number: 1403 • ACR Convergence 2024
Development, Validation and Clinical Use of Health-Related Behaviour Health Fitness Questionnaire (HR-BHF) in Indian (Asian) Subjects Attending a Community Rheumatology Center
MANJIT SALUJA¹ and ARVIND CHOPRA², ¹CENTER FOR RHEUMATIC DISESAES, Pune, Maharashtra, India, ²CENTER FOR RHEUMATIC DISEASES, Pune, Maharashtra, India
Background/Purpose: Our patients often express concerns related to ‘wellbeing’ that are not routinely attended during standard care (including QOL). Alternatively, these concerns are important components…
Abstract Number: 1681 • ACR Convergence 2024
Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase III Study
Anna Zubrzycka-Sienkiewicz¹, Kamilla Klama², Martin Ullmann³, Corinne Petit-Frere³, Andras Illes³, Olga Menang³, Joëlle Monnet³ and Peter Baker³, ¹Reumatika - Centrum Reumatologil", NZOZ, Warszawa, Poland, ²Solumed Centrum Medyczne, Poznań, Poland, ³Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland
Background/Purpose: A therapy transition from the originator to a biosimilar offers significant advantages for patients by lowering medication costs and improving accessibility to treatments. MSB11456…
Abstract Number: 1845 • ACR Convergence 2024
Treg Expansion and IL-6 Induced STAT3 Phosphorylation in CD4+ T Cells Is a Biomarker of Disease Flare in Rheumatoid Arthritis
Amy Anderson¹, Luke Jones², Fiona Rayner³, Jessica Swift¹, Daniel Maunder¹, Henrique de Paula Lemos¹, David Swan⁴, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Gary Reynolds¹, Jasmine Sim¹, Andrew Melville⁵, Stefan Siebert⁵, Iain McInnes⁶, Carl Goodyear⁵, Catharien Hilkens¹, Karim Raza⁷, Christopher Buckley⁸, Kenneth Baker¹, Arthur Pratt³, Andrew Filer⁷ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, Birmingham, United Kingdom, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, ⁵School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁸Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom
Background/Purpose: Understanding the mechanisms that drive disease flares in patients with rheumatoid arthritis (RA) may aid in the development of biomarkers to facilitate targeted treatment…
Abstract Number: 1903 • ACR Convergence 2024
Impact of Multimorbidity on Targeted Synthetic and Biologic Disease-modifying Antirheumatic Drug (ts/bDMARD) Effectiveness in Patients with Rheumatoid Arthritis: A Two Year Follow-up Study from Mexican Adverse Events Registry BIOADAMEX
Vijaya Rivera Teran¹, David Vega Morales², Iris Jazmín Colunga Pedraza³, Sandra Sicsik Ayala⁴, Angel Alejandro Castillo Ortiz⁵, Miguel Angel Saavedra Salinas⁶, Dafhne Miranda Hernández⁷, Fedra Irazoque Palazuelos⁸, Julio César Casasola Vargas⁹, Omar Eloy Muñoz Monroy¹⁰, Sandra Carrillo Vazquez⁸, javier Merayo Chalico¹¹, Guillermo Guaracha Basañez¹², Estefania Torres Valdez¹³, Luis Valdés Corona¹⁴, Angélica Peña Ayala¹⁵, Sergio Durán Barragán¹⁶, Azucena Ramos Sánchez², Aleni Paz Viscarra¹⁴, Erick Adrián Zamora Tehozol¹⁷, Daniel Xibillé Friedman¹⁸ and Jiram Torres Ruiz¹⁹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Instituto Mexicano del Seguro Social, Torreón, Mexico, ⁵Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Merida, Mexico, ⁶División de Investigación en Salud, Hospital de Especialidades Dr. Antonio Fraga Mouret, CMN La Raza, CDMX, Mexico, ⁷Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁹Hospital General de México, “Dr.Eduardo Liceaga”, MEXICO CITY, Mexico, ¹⁰Hospital Central Militar, Mexico City, Mexico, ¹¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, CDMX, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirón", Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Práctica Privada, Mexico City, Mexico, ¹⁵Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Ciudad de Mexico, Distrito Federal, Mexico, ¹⁶Clínica de Investigación en Reumatología, Guadalajara, Mexico, ¹⁷Práctica Privada, Merida, Mexico, ¹⁸Práctica Privada, Cuernavaca, Mexico, ¹⁹INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: To evaluate the impact of multimorbidity on the effectiveness of targeted synthetic and biologic disease-modifying antirheumatic drug (ts/bDMARD), in patients with rheumatoid arthritis in a two-year follow-up.Methods:…
Abstract Number: 2118 • ACR Convergence 2024
Cytotoxic T Lymphocyte Antigen-4 Improves Osteoporosis in Patient with Rheumatoid Arthritis
Yen-An Chang¹ and Ming‑Han Chen², ¹Division of Allergy, Immunology, Rheumatology/Department of Medicint/Taipei Veterans General Hospital, Taipei City, Taiwan (Republic of China), ²Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Rheumatoid arthritis (RA) is recognized as a risk factor for osteoporosis. Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) acts as an inhibitory regulator post-T cell activation,…
Abstract Number: 2216 • ACR Convergence 2024
Additive Impact of Rheumatoid Arthritis and HBcAb+ on All-cause and Cardiovascular Mortality
Leiyi Yang¹, Bo Chen², Qibing Xie³ and Geng Yin⁴, ¹Sichuan University, Cheng Du Shi, Sichuan, China (People's Republic), ²Chenbo, Chendu, Sichuan, China, ³Department of Rheumatology and Immunology, Chengdu, Sichuan, China, ⁴Department of Rheumatology and Immunology, chengdu, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) and hepatitis B both have a high incidence and significant health impacts, possibly sharing a pathogenic connection. Notably, a considerable proportion of…
Abstract Number: 2233 • ACR Convergence 2024
Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
Andrew Concoff¹, Touba Warsi², Sepehr Taghavi², Sudha Kumar², Abigail Patalinghug², Christine Schleif², Brittany Partain³, Joseph Ahearn⁴, Susan Manzi⁵, Michael Mahler⁶, Veena Joy⁷ and Tyler O'Malley⁸, ¹Exagen, Inc., Los Angeles, CA, ²Exagen, Carlsbad, CA, ³Exagen, Boston, MA, ⁴Allegheny Health Network, Wexford, PA, ⁵Allegheny Health Network, Pittsburgh, PA, ⁶Werfen, San Diego, CA, ⁷ThermoFisher, Philadelphia, PA, ⁸Exagen, Vista, CA
Background/Purpose: Studies have found autoantibodies (Ab) directed against heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), peptidyl arginine deiminase 4 (anti-PAD4) and carbamylated proteins (anti-CarP) each have diagnostic…
Abstract Number: 2250 • ACR Convergence 2024
Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity
Elena Joerns¹, Ryan Lennon², Cynthia Crowson², Andrea Lopez-ruiz², Roslin Jose George², Vanessa Kronzer², John Davis² and Elena Myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN
Background/Purpose: Persons with rheumatoid arthritis (RA) have an increased risk of mortality compared to the general population. Seropositivity has been shown to be associated with…
Abstract Number: 2270 • ACR Convergence 2024
Low Yield of Routine Serological Screening for Hepatitis B in Patients with Rheumatoid Arthritis Starting Rituximab Therapy in a Non-Endemic Country
Pauline Bovens¹, Maike Wientjes¹, Nathan den Broeder², David Ten Cate³, Aatke Van der maas⁴ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ³Sint Maartenskliniek, Rotterdam, Netherlands, ⁴St Maartenskliniek, Ubbergen, Netherlands
Background/Purpose: Rituximab (RTX) is an effective and safe treatment for patients with RA, but is associated with an increased risk for reactivation of hepatitis B virus…
Abstract Number: 2394 • ACR Convergence 2024
Perioperative Stress Dose vs Therapeutic Dose Comparison: One-Month Postoperative Outcomes in Moderate and Major Surgeries for Systemic Lupus Erythematous and Rheumatoid Arthritis
Diana Gavilanes¹, Alex Jakubiak², Jhon. F Martinez³ and Anas Atrash⁴, ¹UPMC Health Plan - Harrisburg Pa, Harrisburg, PA, ²Drexel University, Philadelphia, PA, ³BaylorScott&White Health, Waco, TX, ⁴UPMC Health Plan - Harrisburg Pa, Harrisburg, PA
Background/Purpose: Major and moderate surgeries are more common in patients with autoimmune diseases. However, there is limited data available regarding the use of standard doses…
Abstract Number: 2597 • ACR Convergence 2024
The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation
Jia (Sijia) Chen¹, Roopa Madhu², Catherine Manning³, Daniel Montoro⁴, Nataliya Yeremenko⁵, Kevin Wei⁶, ilya Korsunsky¹, Dominique Baeten⁵ and Ellen Gravallese⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital, Dedham, MA, ⁴TenSixty Biosciences, Boston, MA, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: The interleukin-17 (IL-17) family of cytokines consists of 6 evolutionarily conserved cytokines, IL-17A-F. Of these, IL-17A, B, C, and F play diverse roles in…
Abstract Number: PP06 • ACR Convergence 2024
Sweat It Out: How the Sauna Has Helped Me Cope with Rheumatoid Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Since receiving my rheumatoid arthritis (RA) diagnosis in 2015, I have found that one of my top five strategies to manage my symptoms is spending…
Abstract Number: 0034 • ACR Convergence 2024
Arthritogenic Subdoligranulum (S. Dido 7) Is Increased in Individuals At-Risk for and with Early RA and Decreases over Time During Development of Inflammatory Arthritis
Lyndsey Cole¹, Sucai Liu², Brendan Allen², Marie Feser³, Kristen Demoruelle⁴, Kevin Deane⁵, Michael Holers³ and Kristine Kuhn⁶, ¹University of Colorado School of Medicine, Centennial, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO, ⁵University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁶University of Colorado, Aurora, CO
Background/Purpose: Subdoligranulum didolesgii, S. dido 7, is present in a subset of individuals who are at-risk for RA (termed ‘ARI’) and who have clinical RA,…
Abstract Number: 0051 • ACR Convergence 2024
Impact of Tight Junction Proteins on Inflammatory Processes and Microbial Imbalance in Rheumatoid Arthritis
Arkaitz Mucientes¹, jose Manuel Lisbona-Montañez², Patricia Ruiz-Limón³, Sara Manrique-Arija⁴, Aimara García-Studer⁴, Fernando Ortiz-Márquez⁴, Natalia Mena Vázquez⁵ and Antonio Fernández-Nebro⁶, ¹IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, ²University of Malaga, Malaga, Andalucia, Spain, ³IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, ⁴Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, ⁵IBIMA, Málaga, Andalucia, Spain, ⁶Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain
Background/Purpose: The etiology of Rheumatoid Arthritis (RA) is not fully understood. Recent studies point to intestinal permeability as an important factor in the establishment and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].